Harpoon Therapeutics
September 14, 2023 - by Joey Ramson
$HARP is down nearly 20% as of this posting. Most likely due to the fact the AbbVie has recently informed them that they will not be exercising their exclusive licensing option for Harpoon Therapeutics’ HPN217
